药品详细
Chlorthalidone(氯噻酮)
化学结构式图
中文名
氯噻酮
英文名
Chlorthalidone
分子式
C14H11ClN2O4S
化学名
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-sulfonamide
分子量
Average: 338.766
Monoisotopic: 338.012805247
Monoisotopic: 338.012805247
CAS号
77-36-1
ATC分类
C03B 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
A benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. [PubChem]
生产厂家
- Abbott laboratories pharmaceutical products div
- Ascot hosp pharmaceuticals inc div travenol laboratories inc
- Clonmel healthcare ltd
- Ivax pharmaceuticals inc
- Kv pharmaceutical co
- Monarch pharmaceuticals inc
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Pioneer pharmaceuticals inc
- Pliva inc
- Purepac pharmaceutical co
- Sandoz inc
- Sanofi aventis us llc
- Superpharm corp
- Teva pharmaceuticals usa inc
- Usl pharma inc
- Vangard laboratories inc div midway medical co
- Warner chilcott div warner lambert co
- Watson laboratories inc
封装厂家
- Advanced Pharmaceutical Services Inc.
- Amerisource Health Services Corp.
- Apothecon
- A-S Medication Solutions LLC
- AstraZeneca Inc.
- Bryant Ranch Prepack
- Comprehensive Consultant Services Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- H and H Laboratories
- Hl Moore Drug Exchange
- IPR Pharmaceuticals Inc.
- Ivax Pharmaceuticals
- Kaiser Foundation Hospital
- King Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Major Pharmaceuticals
- Medvantx Inc.
- Merckle GmbH
- Monarch Pharmacy
- Murfreesboro Pharmaceutical Nursing Supply
- Mutual Pharmaceutical Co.
- Mylan
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Pharmaceutical Utilization Management Program VA Inc.
- Physicians Total Care Inc.
- Pliva Inc.
- Preferred Pharmaceuticals Inc.
- Prepak Systems Inc.
- Qualitest
- Rebel Distributors Corp.
- Remedy Repack
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Stat Scripts LLC
- UDL Laboratories
- Watson Pharmaceuticals
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
规格
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
药理
| Indication | For management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. | ||||||
| Pharmacodynamics | Chlorthalidone, a monosulfonamyl diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Chlorthalidone is used alone or with atenolol in the management of hypertension and edema. | ||||||
| Mechanism of action | Chlorthalidone inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Chlorthalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism. | ||||||
| Absorption | Absorbed relatively rapidly after oral administration. | ||||||
| Volume of distribution | Not Available | ||||||
| Protein binding | High (75% [58% to albumin]) | ||||||
| Metabolism |
Liver
|
||||||
| Route of elimination | The major portion of the drug is excreted unchanged by the kidneys. | ||||||
| Half life | 40 hours | ||||||
| Clearance | Not Available | ||||||
| Toxicity | Symptoms of overdose include nausea, weakness, dizziness and disturbances of electrolyte balance. | ||||||
| Affected organisms |
|
||||||
| Pathways |
|
理化性质
| Properties | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | ||||||||||||||||||||||||||||||||||||||||||
| Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
||||||||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Deslanoside | Possible electrolyte variations and arrhythmias |
| Diazoxide | Significant hyperglycemic effect |
| Digitoxin | Possible electrolyte variations and arrhythmias |
| Digoxin | Possible electrolyte variations and arrhythmias |
| Dofetilide | Increased risk of cardiotoxicity and arrythmias |
| Indacaterol | Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. |
| Lithium | The thiazide diuretic, chlorthalidone, may increase serum levels of lithium. |
| Tenoxicam | Tenoxicam may antagonize the blood pressure lowering effect of Chlorthalidone. Monitor for changes in the therapeutic effect of Chlorthalidone if Tenoxicam is initiated, discontinued or dose changed. |
| Trandolapril | The thiazide diuretic, Chlorthalidone, may increase the hypotensive effect of Trandolapril. Chlorthalidone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. |
| Treprostinil | Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. |
食物相互作用
- Take with food (increases availability).
收藏